BOOK A CONSULTATION

Name

Email *

Message *

CANSWERIST® via @flipboard









Today's Tweets are Tomorrow's Posts
SOCIALCURRENTSEEby ALTACITIES ®
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.

When you change the way you look at things, the things you look at change

Search This Blog

Monday, May 31, 2010

More evidence of the efficacy of Rituxan® for cancer therapy

Phase III Study Showed First-Line Maintenance Use of Rituxan Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening || http://bit.ly/atkD7r || http://bit.ly/dd2UJg
clipped from www.gene.com

Rituxan is a therapeutic antibody that binds to a specific protein called CD20 found on the surface of cancerous and normal B-cells. In NHL and rheumatoid arthritis (RA), Rituxan works with the body's own immune system to eliminate marked CD20-positive B-cells. Stem cells (B-cell progenitors, those cells that give rise to B-cells) in bone marrow do not have the CD20 protein. B-cells usually regenerate after Rituxan treatment and return to normal levels in about 12 months for most patients.

 blog it

No comments:

SUBSCRIBE to This Blog

Enter your email address:

Delivered by FeedBurner

Today ▶ Canswerist®

▶ SLIDESHOW   ▶ NUZZEL “NEXT” story archive for 15Feb18 ▶ Alzheimer’s Cure in sight?   ▶ Health concerns for the 5...

Privacy Notice

Privacy Notice: The sites and blogs of ALTACITIES conform to these PRIVACY PRACTICES.